Mirum Pharmaceuticals
Mirum Pharmaceuticals is a clinical-stage therapeutics company.
Launch date
Employees
Market cap
€1.8b
Enterprise valuation
€1.8b (Public information from Sep 2024)
Share price
$39.35 MIRM
Foster City California (HQ), San Diego California (founding location)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 19.1m | 77.1m | 186m | 315m | 403m | 509m |
| % growth | - | - | 303 % | 142 % | 69 % | 28 % | 26 % |
| EBITDA | (103m) | (64.7m) | (127m) | (87.4m) | (69.2m) | (36.3m) | 2.4m |
| % EBITDA margin | - | (338 %) | (165 %) | (47 %) | (22 %) | (9 %) | - |
| Profit | (103m) | (84.0m) | (136m) | (163m) | (81.1m) | (33.2m) | 52.4m |
| % profit margin | - | (439 %) | (176 %) | (88 %) | (26 %) | (8 %) | 10 % |
| EV / revenue | - | 17.2x | 7.4x | 7.5x | 6.7x | 5.3x | 4.2x |
| EV / EBITDA | -5.0x | -5.1x | -4.5x | -16.0x | -30.6x | -59.0x | 900.8x |
| R&D budget | 81.6m | 131m | 107m | 103m | - | - | - |
| R&D % of revenue | - | 687 % | 139 % | 55 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $120m | Series A | |
| N/A | $75.0m Valuation: $345m | IPO | |
* | $210m | Post IPO Equity | |
* | N/A | $80.0m | Post IPO Equity |
* | N/A | $275m | Post IPO Convertible |
* | $6.2m | Post IPO Equity | |
| Total Funding | €109m | ||
Related Content
Recent News about Mirum Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Mirum Pharmaceuticals
Edit
ACQUISITION by Mirum Pharmaceuticals May 2022